Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
